Compare Incyte Corporation (INCY) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tyson Foods, Inc. — how do they compare? Incyte Corporation trades at $120.63 (market cap $24.54B), while Tyson Foods, Inc. trades at $56.22 (market cap $19.85B). The key difference: Incyte Corporation is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.62% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TSN | |
|---|---|---|
Market Cap | $24.54B | $19.85B |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $68.75 |
52-Week Low | $81.61 | $50.72 |
Enterprise Value | $20.04B | $27.12B |
Dividend Yield | — | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Tyson Foods (TSN) trades at $55.85, down 2.29% today, reflecting bearish technical signals and mixed fundamentals. Recent Q3 2026 earnings of $0.99 per share beat estimates, but revenue missed expectations amid declining volumes. The company faces headwinds from persistent losses in its beef segment, though chicken and prepared foods remain profitable. Analyst consensus is a 'Buy' with a $68.50 price target, suggesting significant upside potential from current levels.
The outlook hinges on Tyson's ability to stabilize beef margins while leveraging strength in other segments. Investment appeal lies in its low P/S ratio of 0.36 and dividend yield, but risks include volatile commodity costs and execution challenges. Near-term performance will depend on Q3 2026 results and management's guidance update.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
